Your SlideShare is downloading. ×
Ega survey to ms and efta countries michele uda ega
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

Ega survey to ms and efta countries michele uda ega

157
views

Published on


0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
157
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
2
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Survey on good practices and obstaclesto the uptake of the biosimilars marketin Member States and EFTA CountriesMedicamentos Biosimilares: Present y futuroMichele UdaMember of the EGA Board and Chair of the Transparency working group12th of February, Madrid
  • 2. Stakeholders ContactedAll EU MS and EFTA countries;Represented either by: Health authorities and/or Health insurers
  • 3. Responding Countries = 24
  • 4. Outstanding Countries = 5
  • 5. Question 1 – Does your country have specialprescribing rules for biologicals and/ or forbiosimilars?
  • 6. Question 2- In your country, do you havespecific clauses removing biologicals fromautomatic substitution?
  • 7. Question 3 - Does your agency communicateinformation on biosimilars via their websiteto the general public? If yes, what are therecommendations put forward?
  • 8. Question 4 - Does your country havemeasures in place targeting the uptake ofbiosimilars? When were these introduced?
  • 9. Question 5 - Obstacles Listed by Member StatesQuality, safety and efficacy General perception that biosimilar medicines are inferior to innovators; Biosimilars concept not fully accepted/ understood by doctors; Prescribers concerns regarding primarily safety and efficacity of biosimilars; Currently, doctors are reluctant to prescribe biosimilars due to hypothetic uncertainties in safety and effectiveness of biosimilars; Patients’ misperceptions regarding biosimilar medicines;
  • 10. Question 5 - Obstacles Listed by Member StatePrescription practices Reluctance by physicians to prescribe/ deliver biosimilar medicine; Reluctance by doctors to switch brands; There is a widespread belief that biosimilars are inferior to innovators and that they are not interchangeable;
  • 11. Question 5 - Obstacles Listed by Member StateLegislative Issues Lack of regulation;Lack of incentives Lack of incentives to prescribe/deliver biosimilar medicines; No incentives are provided to doctors to use biosimilars through the (hospitals) reimbursement scheme;
  • 12. Question 6 - Uptake Measures Listed by Member StatePrescription rules and Incentives Prescription target/ quota; Enhance the prescription of biosimilars in hospitals; Set-up procedures for usage and substitution; Introduce some incentives for doctors to increase prescription of biosimialrs in patients who are starting the treatment.
  • 13. Question 6 - Uptake Measures Listed by Member StateProcurement procedures (1/2) National and regional hospital tenders for biologicals including biosimilars; Bidding system every year for the status of preferred biological products (biological products grouped together with their biosimilars);
  • 14. Question 6 - Uptake Measures Listed by Member StateProcurement procedures (2/2) Transparent pricing of pharmaceuticals in hospitals; Introduction of a daily lump sum for pathologies treated with biologicals in out-patient care; Another model is "preferred drug" that one drug, the least expensive will be the normal choice; Introduce more price incentives;
  • 15. Question 6 - Uptake Measures Listed by Member StateInformation campaigns (1/2) Provide specific information about biosimilars targeted at the prescribers; Clear and unbiased information from an independent source on the "concept" of biosimilars, their approval process and their safety, will be central; Create awareness for biosimilars;
  • 16. Question 6 - Uptake Measures Listed by Member StateInformation campaigns (2/2) Improve the knowledge of healthcare professionals on biosimilars (e.g. organisation of conferences with all stakeholders); Patient targeted information on the same issues as for doctors is thought to have added benefits;
  • 17. Question 6 - Uptake Measures Listed by Member StateSubstitution (1/2) Clear statement from EMA on the safety of substitution; Clear decisions on automatic substitution- possible or not- is also of importance; Automatic substitution will be reconsidered when biosimilar monoclonals enter the market, at the latest; Define procedures for usage and substitution;Note: 1 ) Substitution: refers to the practice of dispensing one medicine instead of another equivalent and interchangeablemedicine at the pharmacy level without consulting with the prescriber. 2) Automatic Substitution: refers to the practicewhereby a pharmacist is obliged to dispense one medicine instead of another equivalent and interchangeable medicine due tonational or local requirements without consulting with the prescriber.
  • 18. Question 6 - Uptake Measures Listed by Member StateSubstitution (2/2) There is a proposal of the law for implementing therapeutic reference groups; Automatic substitution when initiating treatment with a biological drug; (…), automatic substitution triggers price reductions ("step price"), and it is a very transparent and robust system with appropriate safety mechanism, i.e. doctor’s reservation. Various models are being considered: automatic substitution without limitations, substitution at start of treatment, but not later;
  • 19. Question 6 - Uptake Measures Listed by Member StateOthers Shorter deadline for deciding on the price and inclusion in the system of reimbursement (60 days); A robust regulatory framework is likely to be the best measure to foster uptake, doctors are likely to be somewhat slow in moving towards biosimilars; Increased role of clinicians as fund holders or service managers.
  • 20. EGA Conclusions (1/2)There is a need for clear and unbiasedinformation from independent sources,targeting doctors, on the scientificconcept of biosimilars, their approvalprocess and their safety and efficacy.
  • 21. EGA Conclusions (2/2)Member States should put in placeprescribing guidelines that incentivizephysicians to increase the prescriptionof biosimilars, in addition toreimbursement rules that create thecondition for the uptake of thebiosimilars market.